CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
DC4U is creating a novel allergy treatment that modifies the immune response to allergens, aiming to replace traditional symptom relief methods. Their lead product, designed for grass pollen allergies, seeks to induce long-term tolerance with a shorter treatment duration, addressing a critical need in allergy managemen…
The annual increase in prevalence of allergy related diseases develops at an alarming pace worldwide.
Responsible disease mechanisms are characterised by unwanted immune responses to substances which do not harm healthy individuals.
The allergy therapeutics market is now dominated by symptom alleviating antihistamines, decongestants and corticosteroids.
The main patient need is to get cured with a disease modifying medicine instead of the chronic use of symptom relieving products.
Allergen-speci…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
